Biopharmaceutical company, InflaRx, has opened a new research facility in Ann Arbor, Michigan, USA, to further develop and extend the company’s complement system-based therapeutics.
Opening
“At InflaRx, our primary focus is to discover and develop complement-based therapeutics that can change the way inflammatory diseases are treated by providing innovative solutions for patients with currently unmet medical needs,” said Prof. Niels Riedemann, MD, chief executive officer of InflaRx. “The opening of InflaRx’s new research site in Ann Arbor, the city where our co-founder and CSO, Renfeng Guo, and I met and conducted our post-graduate studies researching the complement system, highlights the Company’s strong connection to cutting edge science and dedication to innovation.”
InflaRx chief scientific officer, Dr Renfeng Guo commented: “The Company’s return to its scientific origins in Ann Arbor by opening this research facility is a significant milestone for InflaRx that will afford us significant advantages as we focus on our mission of discovering and developing superior treatments for inflammatory conditions. I am thrilled to have the opportunity to drive the site’s operations and look forward to taking full advantage of our new capabilities as we accelerate and broaden our pipeline.”
The opening of this research facility represents continued growth of the company in the US and comes at a time when the company’s lead candidate, IFX-1 is advancing through clinical trials with Phase IIb data for its lead indication, hidradenitis suppurativa.